UA112288C2 - Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими - Google Patents
Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режимиInfo
- Publication number
- UA112288C2 UA112288C2 UAA201209849A UAA201209849A UA112288C2 UA 112288 C2 UA112288 C2 UA 112288C2 UA A201209849 A UAA201209849 A UA A201209849A UA A201209849 A UAA201209849 A UA A201209849A UA 112288 C2 UA112288 C2 UA 112288C2
- Authority
- UA
- Ukraine
- Prior art keywords
- forvulation
- antibody
- therapeutic regimens
- therapeutic
- regimens
- Prior art date
Links
- 238000011285 therapeutic regimen Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29538710P | 2010-01-15 | 2010-01-15 | |
| US42205910P | 2010-12-10 | 2010-12-10 | |
| PCT/US2011/020985 WO2011088120A1 (en) | 2010-01-15 | 2011-01-12 | Antibody formulation and therapeutic regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112288C2 true UA112288C2 (uk) | 2016-08-25 |
Family
ID=43858045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201209849A UA112288C2 (uk) | 2010-01-15 | 2011-01-12 | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими |
Country Status (38)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PH12012501364A1 (en) | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| CA2788863C (en) | 2010-02-04 | 2020-07-07 | Reinhard Franz Bolli | Immunoglobulin preparation |
| CA2791951C (en) | 2010-05-20 | 2019-05-14 | Ablynx Nv | Biological materials related to her3 |
| EA201370076A1 (ru) * | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
| JP2014516924A (ja) * | 2011-04-07 | 2014-07-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 粘度が低減された処方物 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20140234330A1 (en) * | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| MX366936B (es) * | 2011-11-23 | 2019-07-31 | Amgen Inc | Uso de un anticuerpo específico alfa4beta7. |
| LT2822590T (lt) * | 2012-03-07 | 2017-01-25 | Eli Lilly And Company | Il-17 antikūno kompozicija |
| ES2622558T3 (es) | 2012-05-14 | 2017-07-06 | Novo Nordisk A/S | Soluciones proteínicas estabilizadas |
| EP2968488A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
| AU2014228553B2 (en) | 2013-03-15 | 2019-01-24 | Amgen Inc. | Methods for treating Crohn's disease using an anti-IL23 antibody |
| SG11201607881SA (en) * | 2014-03-31 | 2016-10-28 | Kirin Amgen Inc | Methods of treating nail and scalp psoriasis |
| AU2015259053B2 (en) | 2014-05-16 | 2020-12-24 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
| EP3185902B1 (en) | 2014-08-26 | 2020-07-29 | Amgen K-A, Inc. | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
| JP6795397B2 (ja) * | 2014-09-10 | 2020-12-02 | 日油株式会社 | 蛋白質吸着抑制剤及び蛋白質吸着抑制方法 |
| EP3763384B1 (en) | 2014-12-03 | 2024-08-28 | CSL Behring AG | Pharmaceutical product with increased stability comprising immunoglobulins |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3349854A4 (en) | 2015-09-17 | 2019-04-03 | Amgen Inc. | PREDICTING THE CLINICAL RESPONSE TO IL23 ANTAGONISTS WITH IL23 PATIENT BIOMARKERS |
| HK1255922A1 (zh) | 2015-11-04 | 2019-09-06 | Astrazeneca Ab | 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子 |
| RU2018124603A (ru) | 2015-12-22 | 2020-01-24 | Эмджен Инк. | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 |
| CN109073949B (zh) | 2016-04-19 | 2022-01-11 | Sage电致变色显示有限公司 | 包括透明导电氧化物层和汇流条的电致变色装置和其形成方法 |
| GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| CA2974531A1 (en) * | 2017-07-26 | 2019-01-26 | Michael Giroux | Safety anchor and roof vent |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| EP3820897A2 (en) | 2018-07-13 | 2021-05-19 | Astrazeneca Collaboration Ventures, LLC | Treating ulcerative colitis with brazikumab |
| EP3927729A4 (en) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | THERAPEUTIC ANTIBODY FORMULATION |
| WO2021050563A1 (en) * | 2019-09-09 | 2021-03-18 | The Rockefeller University | Antibody treatment for lesional tissue of hidradenitis suppurativa |
| CN114401993A (zh) | 2019-09-11 | 2022-04-26 | 博世健康爱尔兰有限公司 | 使用il-17ra抗体治疗非酒精性脂肪肝疾病(nafld)的方法 |
| CN112891530B (zh) * | 2020-06-19 | 2021-08-24 | 北京东方百泰生物科技股份有限公司 | 一种抗il-17ra单克隆抗体的注射制剂 |
| AU2022274319A1 (en) * | 2021-05-12 | 2024-01-04 | Anaptysbio, Inc. | Antibody composition |
| EP4537345A1 (en) * | 2022-06-06 | 2025-04-16 | Fusion Pharmaceuticals Inc. | Methods of dosing therapeutic agents |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000835A (en) | 1911-06-19 | 1911-08-15 | Stewart A Minnick | Calipers. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
| JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Ｉｌ‐２レセプター特異的キメラ抗体 |
| IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ES2238070T3 (es) | 1989-04-21 | 2005-08-16 | Amgen Inc. | Receptor del tnf, proteina ligante del tnf y adn codante para estos. |
| DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
| CA2458875A1 (en) | 1989-05-18 | 1990-11-18 | Yeda Research And Development Company Limited | Tumor necrosis factor (tnf) binding protein ii, its purification and antibodies thereto |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| US5703088A (en) | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| WO1991003553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | TUMOR NECROSIS FACTOR-α AND -β RECEPTORS |
| DK0417563T3 (da) | 1989-09-12 | 2000-11-06 | Hoffmann La Roche | TNF-bindende proteiner |
| JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
| CA2032191C (en) | 1989-12-13 | 1999-05-18 | David Wallach | Expression of the recombinant tumor necrosis factor binding protein i (tbp-i) |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| GB2243569A (en) | 1990-05-02 | 1991-11-06 | Andrew Langdon | Brush with timer |
| ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
| WO1992001002A1 (fr) | 1990-07-11 | 1992-01-23 | Teijin Limited | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
| DK0567566T4 (da) | 1991-01-18 | 2007-10-22 | Amgen Inc | Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme |
| CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| CA2121473C (en) | 1991-10-15 | 2001-05-01 | Michael Mullarkey | Methods and compositions for treating allergic reactions |
| US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JPH07508639A (ja) | 1992-03-30 | 1995-09-28 | イミュネックス・コーポレーション | 腫瘍壊死因子受容体を含む融合蛋白質 |
| DE69327582T2 (de) | 1992-04-30 | 2000-08-03 | Amgen Inc., Thousand Oaks | Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten |
| JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
| WO1994006476A1 (en) | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US6680057B1 (en) | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
| EP0817847B2 (en) | 1995-03-23 | 2009-09-09 | Immunex Corporation | Il-17 receptor |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| WO1997004097A2 (en) | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Human ctla-8 and uses of ctla-8-related proteins |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| US6406867B1 (en) | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
| AU7408998A (en) | 1996-11-27 | 1998-06-22 | Immunex Corporation | Method of regulating nitric oxide production |
| PT1500329E (pt) | 1996-12-03 | 2012-06-18 | Amgen Fremont Inc | Anticorpos humanos que se ligam especificamente ao tnf alfa humano |
| WO1999060127A2 (en) | 1998-05-15 | 1999-11-25 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6635443B1 (en) | 1997-09-17 | 2003-10-21 | Human Genome Sciences, Inc. | Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein |
| US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| ATE464062T1 (de) | 1999-10-04 | 2010-04-15 | Novartis Vaccines & Diagnostic | Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi |
| US20020045213A1 (en) | 2000-03-16 | 2002-04-18 | Shuqian Jing | IL-17 receptor like molecules and uses thereof |
| AR030554A1 (es) | 2000-03-16 | 2003-08-27 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
| US20030180255A1 (en) | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| AU2002246746B2 (en) | 2000-10-18 | 2007-05-31 | Kirin-Amgen, Inc. | Methods for treating rheumatoid arthritis using il-17 antagonists |
| DE60322513D1 (de) | 2002-02-27 | 2008-09-11 | Immunex Corp | Stabilisierte TNFR-Fc Formulierung mit Arginin |
| AU2003280017A1 (en) | 2002-06-27 | 2004-01-19 | Smithkline Beecham Corporation | Methods of treating or preventing ibd with il-18 |
| JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| EP1651190B1 (en) | 2003-08-05 | 2012-09-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
| GB0321703D0 (en) * | 2003-09-16 | 2003-10-15 | Imerys Minerals Ltd | Surface modified fillers for polymer resin compositions |
| WO2005063291A1 (ja) | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| IL159670A0 (en) | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
| JP2008501826A (ja) | 2004-06-04 | 2008-01-24 | デジグナー モレキュールズ インコーポレイテッド | フリーラジカル硬化可能なポリエステル類およびその使用方法 |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| US7704503B2 (en) | 2005-02-14 | 2010-04-27 | Wyeth Llc | Use of IL-17F in diagnosis and therapy of airway inflammation |
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| EA014513B1 (ru) | 2005-08-03 | 2010-12-30 | Иммьюноджен, Инк. | Композиция иммуноконъюгата |
| WO2007037795A2 (en) | 2005-08-05 | 2007-04-05 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| EP2322219A3 (en) | 2005-09-01 | 2013-06-05 | Merck Sharp & Dohme Corp. | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
| EP1931708A1 (en) | 2005-10-18 | 2008-06-18 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
| EP3225233B1 (en) | 2005-11-01 | 2019-08-14 | Wyeth LLC | Sodium chloride solution for drug reconstitution |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| CN101541833B (zh) * | 2006-10-02 | 2014-01-29 | 麒麟-安姆根有限公司 | Il-17受体a抗原结合蛋白质 |
| EP2064237A2 (en) | 2006-10-18 | 2009-06-03 | ZymoGenetics, Inc. | Il-17c antagonists and methods of using the same |
| CA2790018C (en) * | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
| FR2910324B1 (fr) | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| JP2010522564A (ja) | 2007-03-26 | 2010-07-08 | ザイモジェネティクス， インコーポレイテッド | 可溶性ｉｌ−１７ｒａ／ｒｃ融合タンパク質および関連する方法 |
| AU2008266948B2 (en) | 2007-06-13 | 2012-08-23 | Kirin-Amgen, Inc. | IL-17 heteromeric receptor complex |
| WO2009006301A2 (en) | 2007-06-29 | 2009-01-08 | Battelle Memorial Institute | Protein stabilization |
| WO2009026122A1 (en) | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and fc-fusion molecules using polycations |
| EP2250200A2 (en) | 2008-02-21 | 2010-11-17 | Amgen Inc. | Il-17ra-il-17rb antagonists and uses thereof |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| PH12012501364A1 (en) | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| RU2591083C2 (ru) | 2010-10-08 | 2016-07-10 | Новартис Аг | Способы лечения псориаза с использованием антагонистов il-17 |
| TW201307385A (zh) | 2010-10-25 | 2013-02-16 | Genentech Inc | 胃腸炎症和銀屑病以及哮喘的治療 |
| KR20140066124A (ko) * | 2011-04-07 | 2014-05-30 | 글락소스미스클라인 엘엘씨 | 점도가 감소된 제제 |
| JP2014516924A (ja) * | 2011-04-07 | 2014-07-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 粘度が低減された処方物 |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| SG11201607881SA (en) | 2014-03-31 | 2016-10-28 | Kirin Amgen Inc | Methods of treating nail and scalp psoriasis |
| EP3185902B1 (en) | 2014-08-26 | 2020-07-29 | Amgen K-A, Inc. | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
-
2011
- 2011-01-12 PH PH1/2012/501364A patent/PH12012501364A1/en unknown
- 2011-01-12 PT PT171955305T patent/PT3295957T/pt unknown
- 2011-01-12 SI SI201131350T patent/SI2523688T1/en unknown
- 2011-01-12 PL PL11705713T patent/PL2523688T3/pl unknown
- 2011-01-12 KR KR1020127021299A patent/KR101766936B1/ko active Active
- 2011-01-12 MY MYPI2016001562A patent/MY182680A/en unknown
- 2011-01-12 PT PT117057133T patent/PT2523688T/pt unknown
- 2011-01-12 EP EP17195530.5A patent/EP3295957B1/en active Active
- 2011-01-12 HU HUE11705713A patent/HUE035618T2/en unknown
- 2011-01-12 MX MX2012008213A patent/MX349856B/es active IP Right Grant
- 2011-01-12 AU AU2011205402A patent/AU2011205402B2/en active Active
- 2011-01-12 HU HUE17195530A patent/HUE046670T2/hu unknown
- 2011-01-12 EA EA201891433A patent/EA201891433A3/ru unknown
- 2011-01-12 PL PL17195530T patent/PL3295957T3/pl unknown
- 2011-01-12 WO PCT/US2011/020985 patent/WO2011088120A1/en active Application Filing
- 2011-01-12 NZ NZ601125A patent/NZ601125A/en unknown
- 2011-01-12 JP JP2012549047A patent/JP5743234B2/ja active Active
- 2011-01-12 UA UAA201209849A patent/UA112288C2/uk unknown
- 2011-01-12 SI SI201131792T patent/SI3295957T1/sl unknown
- 2011-01-12 US US13/521,999 patent/US8883151B2/en active Active
- 2011-01-12 RS RS20171311A patent/RS56781B1/sr unknown
- 2011-01-12 BR BR112012017150-0A patent/BR112012017150B1/pt active IP Right Grant
- 2011-01-12 HR HRP20171939TT patent/HRP20171939T1/hr unknown
- 2011-01-12 SG SG2012051108A patent/SG182468A1/en unknown
- 2011-01-12 CA CA2787128A patent/CA2787128C/en active Active
- 2011-01-12 RS RS20191335A patent/RS59743B1/sr unknown
- 2011-01-12 IN IN6720DEN2012 patent/IN2012DN06720A/en unknown
- 2011-01-12 LT LTEP17195530.5T patent/LT3295957T/lt unknown
- 2011-01-12 ES ES11705713.3T patent/ES2652637T3/es active Active
- 2011-01-12 ES ES17195530T patent/ES2753216T3/es active Active
- 2011-01-12 CN CN201180012846.1A patent/CN102821787B/zh active Active
- 2011-01-12 EA EA201290653A patent/EA031209B9/ru not_active IP Right Cessation
- 2011-01-12 DK DK17195530.5T patent/DK3295957T3/da active
- 2011-01-12 EP EP11705713.3A patent/EP2523688B1/en active Active
- 2011-01-12 LT LTEP11705713.3T patent/LT2523688T/lt unknown
- 2011-01-12 EP EP19189613.3A patent/EP3632466A1/en not_active Withdrawn
- 2011-01-12 PE PE2012001003A patent/PE20121691A1/es active IP Right Grant
- 2011-01-12 NO NO11705713A patent/NO2523688T3/no unknown
- 2011-01-12 DK DK11705713.3T patent/DK2523688T3/en active
- 2011-01-12 MA MA35124A patent/MA33989B1/fr unknown
- 2011-01-12 SG SG10201604093XA patent/SG10201604093XA/en unknown
- 2011-01-14 AR ARP110100123A patent/AR079903A1/es not_active Application Discontinuation
- 2011-01-14 TW TW100101536A patent/TWI554282B/zh active
-
2012
- 2012-06-24 IL IL220602A patent/IL220602B/en active IP Right Grant
- 2012-06-26 TN TNP2012000335A patent/TN2012000335A1/en unknown
- 2012-07-11 ZA ZA2012/05167A patent/ZA201205167B/en unknown
- 2012-07-13 CL CL2012001966A patent/CL2012001966A1/es unknown
- 2012-08-10 CR CR20120419A patent/CR20120419A/es unknown
- 2012-08-10 CO CO12135074A patent/CO6640206A2/es unknown
-
2014
- 2014-09-29 US US14/499,691 patent/US10072085B2/en active Active
- 2014-12-05 JP JP2014247218A patent/JP2015052017A/ja active Pending
-
2015
- 2015-04-21 AU AU2015202023A patent/AU2015202023B2/en active Active
-
2017
- 2017-08-18 AU AU2017216579A patent/AU2017216579A1/en not_active Abandoned
-
2018
- 2018-01-09 CY CY20181100022T patent/CY1119852T1/el unknown
- 2018-08-02 US US16/053,564 patent/US10808033B2/en active Active
-
2019
- 2019-11-04 CY CY20191101143T patent/CY1122466T1/el unknown
-
2020
- 2020-09-08 US US17/015,029 patent/US11505612B2/en active Active
-
2022
- 2022-10-11 US US18/045,534 patent/US20230192873A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA112288C2 (uk) | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими | |
| JOP20110402B1 (ar) | الأجسام المضادة ل cd38 | |
| MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| IL227658A0 (en) | Pharmaceutical preparations containing human antibodies for 9pcsk | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| IN2014MN00948A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX349004B (es) | Nuevos compuestos. | |
| EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| EA201300016A1 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| MX346644B (es) | Moduladores de receptores canabinoides. | |
| PL2582366T3 (pl) | Kombinacja farmaceutyczna do leczenia bólu | |
| EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
| MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
| HK40112795A (en) | Dosing regimens for the treatment of pompe disease | |
| EA201992775A2 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
| TN2013000265A1 (en) | Anti-cd38 antibodies | |
| PH12013501424B1 (en) | Anti-cd38 antibodies | |
| TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists |